Kidney Cancer Clinical Trials


A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001)

Conditions:   Mesothelioma;   Uveal Melanoma;   Renal Cell Carcinoma;   Cholangiocarcinoma
Intervention:   Drug: Niraparib
Sponsors:   University of Florida;   Tesaro, Inc.
Not yet recruiting - verified June 2017

Learn More

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

Condition:   Renal Cancer
Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
Not yet recruiting - verified June 2017

Learn More

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
Intervention:   Drug: SGI-110 (guadecitabine)
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified April 13, 2017

Learn More

A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Cabozantinib;   Drug: Sunitinib
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified June 2017

Learn More

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Conditions:   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer;   Unclassified Renal Cell Carcinoma
Interventions:   Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Patient Observation;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Biological: Opdivo;   Biological: Yervoy
Sponsor:   Bristol-Myers Squibb
Recruiting - verified June 2017

Learn More

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papillomavirus-Related Cancer in Adult Women After Kidney Transplant

Condition:   Solid Organ Transplantation Recipient
Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 2017

Learn More

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Condition:   Advanced Cancer
Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Biological: BMS-986016
Sponsor:   Bristol-Myers Squibb
Recruiting - verified June 2017

Learn More

Pazopanib Vs. Local Therapy for Renal Cancer With Metastases

Condition:   Carcinoma, Renal Cell
Interventions:   Radiation: Radiation;   Drug: Pazopanib
Sponsor:   University of Texas Southwestern Medical Center
Not yet recruiting - verified June 2017

Learn More

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Conditions:   Non-small Cell Lung Cancer;   Renal Cell Cancer;   Breast Cancer;   Bladder Cancer;   Head and Neck Cancer;   Colorectal Cancer
Intervention:   Drug: SGN-2FF
Sponsor:   Seattle Genetics, Inc.
Recruiting - verified June 2017

Learn More

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Conditions:   Epithelial Ovarian Cancer;   Renal Cell Carcinoma
Intervention:   Drug: HKT288
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified June 2017

Learn More

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Conditions:   Adrenal Cortex Carcinoma;   Adult Alveolar Soft Part Sarcoma;   Adult Clear Cell Sarcoma of Soft Parts;   Adult Hepatocellular Carcinoma;   Adult Rhabdomyosarcoma;   Adult Soft Tissue Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Childhood Hepatocellular Carcinoma;   Childhood Rhabdomyosarcoma;   Childhood Soft Tissue Sarcoma;   Childhood Solid Neoplasm;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Hepatocellular Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Renal Cell Carcinoma;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Conditions:   Esophageal Neoplasms;   Lung Neoplasms;   Mesothelioma;   Thymus Neoplasms;   Neoplasms, Germ Cell and Embryonal
Intervention:   Drug: Mithramycin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 28, 2017

Learn More

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Conditions:   Pancreatic Cancer;   Renal Cell Cancer;   Breast Cancer;   Melanoma;   Ovarian Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Anti-hCD70 CAR PBL
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 20, 2017

Learn More

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: lenvatinib;   Drug: everolimus;   Drug: pembrolizumab;   Drug: Sunitinib
Sponsor:   Eisai Inc.
Recruiting - verified June 2017

Learn More

1-15 of 56
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.